TABLE 2.
Comparison of patients with PVCRBSI with a positive PVC tip culture and patients with PVCRBSI without an available PVC tip culture
| Parameter | Value for the groupa |
P valueb | |
|---|---|---|---|
| Positive PVC tip culture (n = 154) | PVC tip culture not performed (n = 545) | ||
| Median age (range [yr]) | 67 (50–77) | 67 (55–78) | 0.346 |
| Male sex | 96 (62.3) | 362 (66.4) | 0.290 |
| Phlebitis | 79 (51.3) | 545 (100.0) | <0.001 |
| Prior hospital admission | 21 (13.6) | 77 (14.1) | 0.877 |
| Days since hospital admission | |||
| Median no. of days (range) | 8 (5–13) | 6 (4–11) | 0.002 |
| 0–7 | 64 (41.6) | 317 (58.2) | <0.001 |
| >7 or unknown | 90 (58.4) | 228 (41.8) | |
| Days since catheter placement | |||
| Median no. of days (range) | 5 (4–8) | 5 (3–7) | 0.014 |
| 0–3 | 28 (18.2) | 169 (31.0) | 0.002 |
| >3 or unknown | 126 (81.8) | 376 (69.0) | |
| Fever | 149 (96.8) | 529 (97.1) | 0.842 |
| Shock | 4 (2.6) | 13 (2.4) | 0.880 |
| Prior surgery | 22 (14.3) | 53 (9.7) | 0.106 |
| Prior nonsurgical invasive procedure | 14 (9.1) | 65 (11.9) | 0.326 |
| Urinary catheter | 29 (18.8) | 100 (18.3) | 0.892 |
| Cirrhosis | 7 (4.5) | 92 (16.9) | <0.001 |
| Diabetes | 25 (16.2) | 134 (24.6) | 0.029 |
| Pulmonary disease | 13 (8.4) | 44 (8.1) | 0.883 |
| HIV infection | 8 (5.2) | 15 (2.8) | 0.134 |
| Chronic kidney disease | 8 (5.2) | 56 (10.3) | 0.054 |
| Cardiac disease | 75 (48.7) | 169 (31.0) | <0.001 |
| Hematological malignancy | 10 (6.5) | 43 (7.9) | 0.563 |
| Solid organ malignancy | 11 (7.1) | 101 (18.5) | 0.001 |
| Neutropenia | 4 (2.6) | 10 (1.8) | 0.551 |
| Solid organ transplant | 4 (2.6) | 27 (5.0) | 0.210 |
| Corticosteroid therapy | 28 (18.2) | 100 (18.3) | 0.962 |
| McCabe, ultimately or rapidly fatal outcome | 44 (28.6) | 229 (42.0) | 0.003 |
| Previous ABTc | 38 (24.7) | 128 (23.5) | 0.759 |
| Beta-lactams | 26 (16.9) | 80 (14.7) | 0.501 |
| Penicillins | 13 (8.4) | 39 (7.2) | 0.591 |
| Third-generation cephalosporins | 11 (7.1) | 32 (5.9) | 0.562 |
| Carbapenems | 1 (0.6) | 17 (3.1) | 0.088 |
| Aminoglycosides | 4 (2.6) | 2 (0.4) | 0.023 |
| Glycopeptides | 3 (1.9) | 10 (1.8) | 0.927 |
| Fluoroquinolones | 9 (5.8) | 44 (8.1) | 0.356 |
| Linezolid | 2 (1.3) | 6 (1.1) | 0.839 |
| Current ABT | 23 (14.9) | 113 (20.7) | 0.108 |
| Betalactams | 15 (9.7) | 61 (11.2) | 0.609 |
| Penicillins | 7 (4.5) | 30 (5.5) | 0.639 |
| Third-generation cephalosporins | 7 (4.5) | 21 (3.9) | 0.699 |
| Carbapenems | 0 (0.0) | 5 (0.9) | 0.233 |
| Aminoglycosides | 2 (1.3) | 7 (1.3) | 0.989 |
| Glycopeptides | 1 (0.6) | 5 (0.9) | 0.999 |
| Fluoroquinolones | 5 (3.2) | 40 (7.3) | 0.068 |
| Linezolid | 0 (0.0) | 1 (0.2) | 0.999 |
a
Values are given as number of patients (percentage) unless otherwise indicated.
b
Significant values are in boldface.
c
ABT, antibiotic therapy.